News | July 24, 2007

Varian Demos I-Response Software for Tumor Assessment

July 25, 2007 – Varian Medical Systems recently displayed its I-Response software created by Cedara, that shows how tumors are responding to treatment at the biological level, reportedly before changes in tumor shape or size become visible, at the American Association of Physicists in Medicine (AAPM) annual meeting, July 22-26, in Minneapolis, MN.

The I-Response tool tracks changes in tumor tissue at the cellular and metabolic levels over time using sophisticated PET/CT analysis and a unique MR technique called functional diffusion mapping (fDM). This provides the potential for clinicians to monitor the impact of anti-cancer drugs and radiation therapy early in the course of treatment, so they can adapt their treatment strategies and personalize treatment plans.

For more information: www.varian.com

Related Content

The Reflexion combination PET-CT linac, on display at ASTRO 2018. The system uses PET radiotracer emissions to track tumors directly without the need for margins to account for respiratory motion. #ASTRO18 #ASTRO2018 #ASTRO

The Reflexion combination PET-CT linac, on display at ASTRO 2018. The system uses PET radiotracer emissions to track tumors directly without the need for margins to account for respiratory motion. 

News | Radiation Therapy | October 30, 2018
October 30, 2018 - Displayed for the first time at ...
Sponsored Content | Webinar | Radiation Therapy | August 28, 2018
Respiratory tumor motion often complicates the delivery of precision radiation treatment.
Magseed magnetic marker
Technology | Tumor Tracking Systems | July 20, 2018
Endomag, the surgical guidance company, received 510(k) clearance from the U.S.
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
Study shows tissue marker reduces radiation target volumes, produces many other advantages

These CT images show placement of a 3-D fixed array implanted fiducial (3-D marker) at the time of oncoplastic tumor resection. The original LCTV (LCTVo) was retrospectively re-contoured by the radiation oncologist (LCTVro) and breast surgeon (LCTVbs). Thereafter, both re-contours were combined to create the collaborative LCTV (LCTVc), which required agreement of both the radiation oncologist and breast surgeon. Volume differences between the original LCTV (LCTVo) and the collaborative LCTVc were then evaluated, and demonstrated a mean and median reduction in LCTV.

Feature | Tumor Tracking Systems | November 06, 2017 | By William Hall, M.D.
Radiation planning for breast cancer relies on accurate delineation of the post-lumpectomy target volume as identified...
El Camino Hospital to Offer Calypso 4-D Localization System
News | Radiation Therapy | July 21, 2017
El Camino Hospital (Mountain View, Calif.) announced the installation of a new Calypso 4-D Localization System and will...
cancer immunotherapy, development, Axel Hoos, Nature Reviews, imaging
News | Oncology Related Products | March 31, 2016
In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current immunotherapy...
Philips, Intellispace Portal 8.0, oncology suite, EASL, RSNA 2015
Technology | Tumor Tracking Systems | December 02, 2015
 Philips announced IntelliSpace Portal 8.0, the latest edition of its advanced data sharing, analytics and...
PET/CT, lung cancer, follow-up, tumor tracking, nuclear imaging, trial
News | February 23, 2015
New research from Johns Hopkins School of Medicine reveals a high value for scans which could lead to future change of...
Carestream, Vue PACS, lesion management, oncology, tumor, Dana-Farber
News | February 04, 2015
Radiologists at the prestigious Dana-Farber Cancer Institute (Boston, Mass.) are using Carestream’s lesion management ...